Real-World Osilodrostat Effectiveness and Safety in Nonpituitary Cushing Syndrome
The Journal of Clinical Endocrinology & Metabolism · 22.04.2026 · 111 (5) · 1287-1298
DOI: 10.1210/clinem/dgaf633 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 19.11.2025. Verfasst von Antoine Tabarin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetes and Nutrition, Centre de Référence des Maladies Rares de la Surrénale, CHU de Bordeaux, 33604 Pessac, France. Hauptthemen laut MEDLINE: Cushing Syndrome. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Recordati AG (Rare Diseases Branch).
Abstract (Originalsprache)
Context
Osilodrostat's clinical development program mostly enrolled Cushing disease patients. Data in nonpituitary Cushing syndrome (CS) patients are limited.
Objective
This work aims to evaluate osilodrostat effectiveness and safety in nonpituitary CS in real-world practice in France.
Methods
A retrospective, observational study (LINC 7; NCT05633953) was conducted in a multicenter institutional practice setting. Data for patients who initiated osilodrostat under the French Autorisation Temporaire d’Utilisation program or, once approved, in routine clinical practice were extracted retrospectively for 36 months or less (2019-2022). Participants included 103 adult nonpituitary CS patients: ectopic adrenocorticotropin secretion (EAS), n = 53; adrenocortical carcinoma (ACC), n = 19; adrenal adenoma (AA), n = 17; and bilateral adrenal nodular disease (BND), n = 14. Forty-three patients remained on osilodrostat throughout the observation period. Median (minimum-maximum) osilodrostat exposure and baseline dose were 177 days (1-1178 days) and 5.0 mg/day (1-60 mg/day), respectively. The main outcome measure was the proportion with mean urinary free cortisol (mUFC) less than or equal to the upper limit of normal (ULN) at Wk 12 (modified intention-to-treat [mITT] population: all enrolled patients with ≥12 weeks' follow-up, excluding patients without Wk 12 mUFC for nonsafety reasons).
Results
Osilodrostat was initiated and titrated based on investigator judgment. Cortisol decreased by Wk 4, remaining stable thereafter. Twenty-three of 52 patients (mITT, 44.2%; 95% CI, 30.5%-58.7%) had mUFC less than or equal to the ULN at Wk 12 (missing values reported as nonresponders). Forty-five of 52 had Wk 12 mUFC available; the proportions with mUFC less than or equal to the ULN by etiology were as follows: EAS, n = 12/29 (41%); ACC, n = 4/6; AA, n = 1/3; and BND, n = 6/7. The most common (≥15%) treatment-emergent adverse events were adrenal insufficiency (28%) and hypokalemia (18%). Twenty-nine patients (EAS, n = 24; ACC, n = 5) died from adverse events (n = 1 assessed as osilodrostat related by investigator), most commonly neoplasm progression (n = 11).
Conclusion
Osilodrostat is a suitable treatment for endogenous CS of various nonpituitary etiologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Diabetes and Nutrition, Centre de Référence des Maladies Rares de la Surrénale, CHU de Bordeaux, 33604 Pessac, France.
- Department of Endocrinology, Centre de Référence des Maladies Rares de la Surrénale, Hôpital Cochin, AP-HP, and Université Paris-Cité, 75014 Paris, France.
- Department of Endocrinology, CHU de Reims, 51100 Reims, France.
- Department of Endocrinology, Hôpital Louis Pradel, Hospices Civils de Lyon Bron Cedex, Lyon 1 University, 69500 Lyon, France.
- Université de Rouen Normandie, INSERM, NorDiC UMR 1239, Department of Endocrinology, Diabetes and Metabolic Diseases, CHU Rouen, 76000 Rouen, France.
- Department of Endocrinology, CHU de Nantes, 44093 Nantes, France.
ORCID-Profile: Antoine Tabarin, Jérôme Bertherat, Hervé Lefebvre, Delphine Drui, Justine Cristante
Förderung
- Recordati AG (Rare Diseases Branch)
Zitieren
APA
Tabarin, A., Bertherat, J., Decoudier, B., Lasolle, H., Lefebvre, H., Drui, D., Vaillant, C., Morera, J., Castinetti, F., Cristante, J., Chevalier, N., Fodil-Cherif, S., Young, J., Piacentini, A., Agbotounou, W., Maldonado, M., Mueller, A., & Scheyer, N. (2026). Real-World Osilodrostat Effectiveness and Safety in Nonpituitary Cushing Syndrome. The Journal of Clinical Endocrinology & Metabolism, 111(5), 1287-1298. https://doi.org/10.1210/clinem/dgaf633
Vancouver
Tabarin A, Bertherat J, Decoudier B, Lasolle H, Lefebvre H, Drui D, et al. Real-World Osilodrostat Effectiveness and Safety in Nonpituitary Cushing Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2026;111(5):1287-1298. doi:10.1210/clinem/dgaf633
BibTeX
@article{Tabarin2026,
author = {Tabarin, Antoine and Bertherat, Jérôme and Decoudier, Bénédicte and Lasolle, Hélène and Lefebvre, Hervé and Drui, Delphine and Vaillant, Charly and Morera, Julia and Castinetti, Frédéric and Cristante, Justine and Chevalier, Nicolas and Fodil-Cherif, Sarah and Young, Jacques and Piacentini, Andrea and Agbotounou, Wence and Maldonado, Mario and Mueller, Arnd and Scheyer, Nicolas},
title = {Real-World Osilodrostat Effectiveness and Safety in Nonpituitary Cushing Syndrome},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
volume = {111},
number = {5},
pages = {1287--1298},
doi = {10.1210/clinem/dgaf633}
}
EUVIMED